{
  "id": "5e5e50751af46fc13000000b",
  "type": "factoid",
  "question": "What classes of drugs does Retapamulin belong to?",
  "ideal_answer": "Retapamulin is a member of the pleuromutilin family of antibiotics.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28874907",
    "http://www.ncbi.nlm.nih.gov/pubmed/22777229",
    "http://www.ncbi.nlm.nih.gov/pubmed/23793314",
    "http://www.ncbi.nlm.nih.gov/pubmed/19436611",
    "http://www.ncbi.nlm.nih.gov/pubmed/18041900",
    "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
    "http://www.ncbi.nlm.nih.gov/pubmed/18341664",
    "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
    "http://www.ncbi.nlm.nih.gov/pubmed/16940066",
    "http://www.ncbi.nlm.nih.gov/pubmed/28533232"
  ],
  "snippets": [
    {
      "text": "Retapamulin 1% ointment is a unique topical antibiotic formulation that may be a suitable option for the treatment of clinically infected",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22777229",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin 1% is effective for the treatment of atopic dermatitis infected with S aureus, and demonstrates efficacy against both methicillin-susceptible and methicillin-resistant strains. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22777229",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pleuromutilins have a potential to be developed as a new class of antibiotics for systemic use in humans. In the current study, we investigated the relationship between pleuromutilins, including valnemulin, tiamulin, and retapamulin, and 13 other antibiotics representing different mechanisms of action, against methicillin-susceptible and -resistant S. aureus both in vitro and in an experimental Galleria mellonella model",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874907",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "he eight antibiotics, azithromycin, clarithromycin, erythromycin, fusidic acid, mupirocin, retapamulin, rifampin, and telithromycin, had diverse targets and mechanisms of action. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28533232",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18341664",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin: a newer topical antibiotic.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23793314",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Retapamulin is the first agent in the new pleuromutilin class of antibacterials to become commercially available for clinical use in humans.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifically designed for use as a topical agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436611",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin belongs to a newly developed class of antibiotics for the treatment of uncomplicated skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18341664",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is a semisynthetic pleuromutilin compound with in vitroactivity against Gram-positive bacteria, no cross-resistance to other classes of antimicrobial agents in current use and a low potential for development of resistance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18041900",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is a semisynthetic pleuromutilin derivative being developed as a topical antibiotic for treating bacterial infections of the skin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16940066",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES\n\nRetapamulin is the first agent of the pleuromutilin class formulated as a topical antibacterial for treating skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is the first agent of the pleuromutilin class formulated as a topical antibacterial for treating skin infections . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is the first agent in the new pleuromutilin class of antibacterials to become commercially available for clinical use in humans.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18389088",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifically designed for use as a topical agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19436611",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Retapamulin is a semisynthetic pleuromutilin derivative being developed as a topical antibiotic for treating bacterial infections of the skin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16940066",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In vitro activity against anaerobes of retapamulin, a new topical antibiotic for treatment of skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Retapamulin is the first agent of the pleuromutilin class formulated as a topical antibacterial for treating skin infections.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350985",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "antibiotics"
}